Who
Carl L. G. Hansen
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, AbCellera Biologics.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $144.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 May 2021
- Last trade
- 1 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jan 2026filed 5 Jan 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,106,505 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,106,505 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,730,109 at $0.00 | filing |
| 25 Nov 2024filed 26 Nov 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,125 at $0.00 | filing |
| 25 Nov 2024filed 26 Nov 2024 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $152K56,125 at $2.70 | filing |
| 20 Sep 2024filed 24 Sep 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,125 at $0.00 | filing |
| 20 Sep 2024filed 24 Sep 2024 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $152K56,125 at $2.70 | filing |
| 31 May 2024filed 3 Jun 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,125 at $0.00 | filing |
| 31 May 2024filed 3 Jun 2024 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $152K56,125 at $2.70 | filing |
| 26 Feb 2024filed 27 Feb 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,125 at $0.00 | filing |
| 26 Feb 2024filed 27 Feb 2024 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $152K56,125 at $2.70 | filing |
| 14 Jan 2024filed 16 Jan 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,095,532 at $0.00 | filing |
| 23 Nov 2023filed 27 Nov 2023 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,125 at $0.00 | filing |
| 23 Nov 2023filed 27 Nov 2023 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $152K56,125 at $2.70 | filing |
| 24 Aug 2023filed 25 Aug 2023 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,125 at $0.00 | filing |
| 24 Aug 2023filed 25 Aug 2023 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $152K56,125 at $2.70 | filing |
| 26 May 2023filed 30 May 2023 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,125 at $0.00 | filing |
| 26 May 2023filed 30 May 2023 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $152K56,125 at $2.70 | filing |
| 22 Feb 2023filed 23 Feb 2023 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,125 at $0.00 | filing |
| 22 Feb 2023filed 23 Feb 2023 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $152K56,125 at $2.70 | filing |
News
AbCellera Biologics (NASDAQ:ABCL) Research Coverage Started at UBS GroupABCL · themarketsdaily.com · 15 Oct 2026Head to Head Review: Surrozen (NASDAQ:SRZN) vs. AbCellera Biologics (NASDAQ:ABCL)ABCL · tickerreport.com · 14 Oct 2026Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)ABCL · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Carl L. G. Hansen; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.